rs137852428
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PS4PS2PP1_StrongPP4_ModeratePP3
This summary comes from the ClinGen Evidence Repository: The c.1834C>T (p.Arg612Cys) variant is present in 3 hemizygotes in gnomAD v2.1.1, so PM2_Supporting in not met. The REVEL score of 0.88 which meets PP3 criteria (threshold >0.6). Thirty-two patients were reported with mild-moderate hemophilia A in a single publication and over 100 individuals were identified in the My Life Our Future Cohort, meeting F8 phenotype criteria for PP4_Moderate and PS4_Very strong (PMID:18691168, 29296726). This variant has been associated with mostly mild, but also moderate and severe, hemophilia A with and without inhibitors to factor replacement therapies. This may be in part because the variant has also been associated with discrepant factor VIII activity levels, with chromogenic assays (two-stage) being 2-fold lower than one stage assays (EAHAD database; PMID:32232366). The variant has been reported to segregate with hemophilia A in greater than 6 meioses across two families (PP1_Strong; PMID:9292523). This variant has also been found to have at least one de novo occurrence in the mother of a proband, where the proband was found to have the unaffected maternal grandfather's allele via haplotype analysis (PS2; PMID:9292523). Additionally, this variant has been reported in patients with and without a history of inhibitors to factor replacement products (EAHAD database). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel for F8: PS2, PS4_Very strong, PP1_Strong, PP3 and PP4_Moderate. LINK:https://erepo.genome.network/evrepo/ui/classification/CA255129/MONDO:0010602/071
Frequency
Consequence
NM_000132.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F8 | NM_000132.4 | c.1834C>T | p.Arg612Cys | missense_variant | 12/26 | ENST00000360256.9 | NP_000123.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
F8 | ENST00000360256.9 | c.1834C>T | p.Arg612Cys | missense_variant | 12/26 | 1 | NM_000132.4 | ENSP00000353393.4 | ||
F8 | ENST00000647125.1 | n.*1710C>T | non_coding_transcript_exon_variant | 13/14 | ENSP00000496062.1 | |||||
F8 | ENST00000647125.1 | n.*1710C>T | 3_prime_UTR_variant | 13/14 | ENSP00000496062.1 |
Frequencies
GnomAD3 genomes AF: 0.00000894 AC: 1AN: 111816Hom.: 0 Cov.: 22 AF XY: 0.0000294 AC XY: 1AN XY: 33994
GnomAD3 exomes AF: 0.0000218 AC: 4AN: 183438Hom.: 0 AF XY: 0.0000442 AC XY: 3AN XY: 67884
GnomAD4 exome AF: 0.0000100 AC: 11AN: 1097783Hom.: 0 Cov.: 30 AF XY: 0.0000110 AC XY: 4AN XY: 363141
GnomAD4 genome AF: 0.00000894 AC: 1AN: 111816Hom.: 0 Cov.: 22 AF XY: 0.0000294 AC XY: 1AN XY: 33994
ClinVar
Submissions by phenotype
Hereditary factor VIII deficiency disease Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 08, 2024 | Variant summary: F8 c.1834C>T (p.Arg612Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.2e-05 in 183438 control chromosomes (gnomAD). c.1834C>T (also known as Arg593Cys) has been reported in the literature in multiple individuals affected with Factor VIII Deficiency (Hemophilia A) (examples: Eckhardt_2009, and Rosset_2013). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 23711237, 19548904). ClinVar contains an entry for this variant (Variation ID: 10236). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, reviewed by expert panel | curation | ClinGen Coagulation Factor Deficiency Variant Curation Expert Panel, Clingen | Feb 09, 2024 | The c.1834C>T (p.Arg612Cys) variant is present in 3 hemizygotes in gnomAD v2.1.1, so PM2_Supporting in not met. The REVEL score of 0.88 which meets PP3 criteria (threshold >0.6). Thirty-two patients were reported with mild-moderate hemophilia A in a single publication and over 100 individuals were identified in the My Life Our Future Cohort, meeting F8 phenotype criteria for PP4_Moderate and PS4_Very strong (PMID: 18691168, 29296726). This variant has been associated with mostly mild, but also moderate and severe, hemophilia A with and without inhibitors to factor replacement therapies. This may be in part because the variant has also been associated with discrepant factor VIII activity levels, with chromogenic assays (two-stage) being 2-fold lower than one stage assays (EAHAD database; PMID: 32232366). The variant has been reported to segregate with hemophilia A in greater than 6 meioses across two families (PP1_Strong; PMID: 9292523). This variant has also been found to have at least one de novo occurrence in the mother of a proband, where the proband was found to have the unaffected maternal grandfather's allele via haplotype analysis (PS2; PMID: 9292523). Additionally, this variant has been reported in patients with and without a history of inhibitors to factor replacement products (EAHAD database). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel for F8: PS2, PS4_Very strong, PP1_Strong, PP3 and PP4_Moderate. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1995 | - - |
Pathogenic, no assertion criteria provided | research | ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Jun 15, 2022 | PS3, PS4, PP3, PP5 - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 08, 2024 | Published functional studies demonstrate that R612C reduces factor VIII activity, and leads to intracellular accumulation and subsequent degradation of the F8 protein (PMID: 10691849); This variant is associated with the following publications: (PMID: 12195713, 11858487, 7794769, 8281136, 35014236, 31064749, 1908096, 7728145, 15682412, 1301932, 9569189, 21251204, 19473423, 11554935, 26057490, 11341489, 10404764, 29296726, 33245802, 32897612, 35047849, 10691849) - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 06, 2022 | PP1_strong, PP3, PP5, PM3_supporting, PS3, PS4_moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jun 26, 2023 | The F8 c.1834C>T; p.Arg612Cys variant (rs137852428), also known as Arg593Cys, is reported in multiple patients associated with mild or moderate hemophilia (See Factor VIII database and references therein, Antonarakis 1995, Diamond 1992, Higuchi 1991, Markoff 2009, Trampus Bajika 2015). This variant is reported in ClinVar (Variation ID: 10236), and found in the general Latino/Admixed American population with an allele frequency of 0.01% (4/27431 alleles, including 3 hemizygotes) in the Genome Aggregation Database. The arginine at codon 612 is highly conserved and computational analyses predict that this variant is deleterious (REVEL: 0.808). Based on available information, this variant is considered to be pathogenic. References: Factor VIII variant database: https://f8-db.eahad.org/index.php Antonarakis SE et al. Molecular etiology of factor VIII deficiency in hemophilia A. Hum Mutat. 1995;5(1):1-22. PMID: 7728145. Diamond C et al. Amino acid substitutions in conserved domains of factor VIII and related proteins: study of patients with mild and moderately severe hemophilia A. Hum Mutat. 1992;1(3):248-57. PMID: 1301932. Higuchi M et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7405-9. PMID: 1908096. Markoff A et al. Combined homology modelling and evolutionary significance evaluation of missense mutations in blood clotting factor VIII to highlight aspects of structure and function. Haemophilia. 2009 Jul;15(4):932-41. PubMed: 19473423. Trampus Bakija A et al. Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys). Blood Transfus. 2015 Oct;13(4):622-30. PubMed: 26057490. - |
Familial aortopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 08, 2024 | - - |
Hereditary factor IX deficiency disease Pathogenic:1
Pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Feb 01, 2019 | - - |
Thrombophilia, X-linked, due to factor 8 defect Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at